Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
February 11, 2025
Biotechnology
-
-
Oncocyte Prices $29.1 Million Equity Offering
February 10, 2025
-
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
February 7, 2025
-
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
February 5, 2025
-
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
February 5, 2025
-
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
February 5, 2025
-
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
January 31, 2025
-
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
January 29, 2025
-
HOPE Therapeutics(TM), Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
January 28, 2025
-
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
January 28, 2025
-
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
January 17, 2025
-
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
January 17, 2025
-
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
January 14, 2025
-
Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform
January 13, 2025
-
Quantum-Si Launches Platinum® Pro: The End-to-End Solution for Deeper Insights in Proteomics
January 13, 2025
-
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline
January 8, 2025